Astellas To Sell Low-Margin Drug Plant To Nichi-Iko For Outsourcing
This article was originally published in PharmAsia News
Astellas Pharma reportedly plans to sell to Nichi-Iko Pharmaceutical its 400-employee plant in Fuji, Japan, to serve as an outsource production site for the seller.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.